Skip to content

Can Skin Bacteria Treat Atopic Dermatitis?

Search Clinical Trials

Trial Objectives


Many varieties of bacteria live naturally on human skin. Researchers in the national TIME-2 study want to find out if one of these bacteria, called Staphylococcus hominis or S. hominis, can safely and effectively help reduce symptoms of atopic dermatitis (eczema).

Volunteers in this study will be randomly assigned to receive either a gel containing S. hominis or a placebo (a medication containing no active ingredient).  Study participants will receive both the assigned gel or placebo treatment and a corticosteroid topically for two weeks, followed by 12 weeks of treatment without the corticosteroid. Swab samples will be collected from participants’ skin during clinic visits. They also will be monitored for changes in symptoms and side effects.
 

Who Can Participate


Adults or children 12 and older with atopic dermatitis and who test positive for Staphyloccus aureus bacteria on their skin during the screening visit.

Age: 12+ Gender: Any

Estimated Time Commitment


7 study visits over approximately 20 weeks

Payment & Reimbursement


Payment: Provided

Travel Reimbursement: Not Available

Trial Contact


For more information, contact:

Tyler Swenson
720.945.8628

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


NIAID

Principal Investigators

  • Mark Boguniewicz

    Mark Boguniewicz, MD

  • Donald Y M Leung

    Donald Y M Leung, MD, PhD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required